Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;40(9):1791-1802.
doi: 10.1007/s10096-021-04282-7. Epub 2021 Jun 4.

Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis

Affiliations
Review

Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis

Soumia Cherif et al. Eur J Clin Microbiol Infect Dis. 2021 Sep.

Abstract

We conducted a meta-analysis of published data to update and estimate the prevalence of HPV in ovarian cancer. A comprehensive literature search was performed according to the PRISMA guidelines. Eligible articles published from 1989 until 2020 by searching Web of Sciences, Pubmed, Embase, and the Cochrane Library Central databases were gathered. A pooled estimation of HPV prevalence with a 95% confidence interval (CI) was calculated based on a random effect model. Quantitative assessment of heterogeneity was explored using Cochrane test and I2. Additionally, publication bias, sensitivity, meta-regression, and subgroup analyses were also performed. Twenty-nine studies involving 2280 patients with ovarian cancer were included. The statistical heterogeneity was high (I2 = 88%, P<0.0001). The pooled prevalence of HPV in ovarian cancer cases was 15.9% (95% CI, 11-22). In subgroup analyses, the highest prevalence of HPV was reported by studies from Asia (30.9%; 95% CI, 20-44) and Eastern Europe (29.3%; 95% CI, 4.4-78). Furthermore, the most frequently detected HPV genotype was HPV16 (54%; 95% CI, 27.9-55), followed by HPV18 (23.2%; 95% CI, 18.8-28.2). Our meta-analysis suggests a great difference in the prevalence of HPV detected in ovarian cancer by different studies, which is not seen in strongly HPV-associated cancers such as cervical cancer. However, the prevalence varied markedly by geographic region. Considering the substantial heterogeneity found, more studies with control groups and precise assays measuring HPV mRNA expression are needed to further evaluate the link and causative aetiology between HPV and ovarian cancer.

Keywords: Etiologic agent; HPV prevalence; Ovarian malignancy; Subgroup analysis; Worldwide.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of the studies selected for this meta-analysis
Fig. 2
Fig. 2
Forest plot showing HPV rate and 95% confidence intervals in ovarian cancer studies based on random-effect model
Fig. 3
Fig. 3
Sensitivity analysis showing the impact of exclusion of any study on the summary effect
Fig. 4
Fig. 4
Funnel plot of studies included in the meta-analysis. The distribution of the studies (dots) is asymmetric suggesting an evidence of publication bias that is also found by Egger’s regression test (P=0.006) and Begg and Mazumdar rank correlation (P=0.5)

Similar articles

Cited by

References

    1. Hassan ZK, Hafez MM, Kamel MM, Zekri ARN. Human papillomavirus genotypes and methylation of CADM1, PAX1, MAL and ADCYAP1 genes in epithelial ovarian cancer patients. Asian Pac J Cancer Prev. 2017;18(1):169–176. doi: 10.22034/APJCP.2017.18.1.169. - DOI - PMC - PubMed
    1. Rosa MI, Silva GD, de Azedo Simões PW, Souza MV, Panatto AP, Simon CS, Madeira K, Medeiros LR. The prevalence of human papillomavirus in ovarian cancer: a systematic review. Int J Gynecol Cancer. 2013;23(3):437–441. doi: 10.1097/IGC.0b013e318280f3e0. - DOI - PubMed
    1. Cass I, Karlan BY. Ovarian cancer symptoms speak out--but what are they really saying? J Natl Cancer Inst. 2010;102(4):211–212. doi: 10.1093/jnci/djp525. - DOI - PubMed
    1. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32. doi: 10.20892/j.issn.2095-3941.2016.0084. - DOI - PMC - PubMed
    1. Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, Mosgaard BJ, Nordin A, Rosen B, Engholm G, Gjerstorff ML, Hatcher J, Johannesen TB, McGahan CE, Meechan D, Middleton R, Tracey E, Turner D, Richards MA, Rachet B. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol. 2012;127(1):75–82. doi: 10.1016/j.ygyno.2012.06.033. - DOI - PubMed